Skip to main content
Tempus logo

Tempus

Updated Mar 23, 2026

Tempus's full profile: funding, valuation, competitors, and the people behind the company.

🇺🇸United StatesPublicAI Healthcare

Out of 100

🇺🇸

HQ

United States

🗓

Founded

2015

💰

Raised

$1.05B

🏷️

Stage

Public

👥

Team

2500

Tempus is an AI-driven oncology and precision medicine company founded in 2015 that utilizes machine learning and data analysis to improve cancer treatment outcomes. The platform aggregates and analyzes vast datasets including clinical data, imaging, molecular information, and outcomes to identify personalized treatment strategies for cancer patients. Tempus's core technology uses artificial

Is this your company? Claim it →

Key Facts

  • Tempus is valued at $8.1B as of March 2026.
  • Tempus has raised a total of $1.05B in disclosed funding across 5 funding rounds.
  • Tempus was founded in 2015 by Eric Lefkofsky and is headquartered in United States.
  • Tempus employs approximately 2500 people.
  • Tempus operates in the AI Healthcare category and is currently at the Public stage.
  • Tempus has an Awaira Score of 84/100, ranking it among the highly notable AI companies on Awaira.
  • Tempus's most recent funding round was a IPO closed in July 2021.

Source: Awaira · Updated Mar 23, 2026

$8.1B

Post-money

$1.05B

All rounds

84/100

2015

2500 employees

Strengths

Raised over $1.05B — one of the best-funded AI companies

Unicorn status with $8.1B valuation

Elite Awaira Score of 84/100

Analysis based on publicly available data. Not investment advice.

5

Total Rounds

$90M

Avg Round Size

5.6yr

Funding Span

Tempus raised 5 rounds over 5.6 years, averaging $90M per round — a pace of roughly one round every 13 months.

⚠️ ESTIMATE
💵Est. Annual Revenue
$50M–$500M estimated ARR

Awaira estimate based on public data. Not financial advice.

How does Tempus stack up against competitors?

MetricTempusButterfly NetworkAlanAbridge
Awaira Score84/10085/10083/10076/100
Total Raised$1.05B$370M$750M$800M
Valuation$8.1B$957M$5.83B$5.3B
StagePublicPublicSeries DSeries E
Founded2015201120162018
Employees2500500-1000500-1000120
Country🇺🇸🇺🇸🇫🇷🇺🇸
E

Eric Lefkofsky

Founder & CEO

View founder profile →
StagePublic
Employees2500
Country🇺🇸 United States
Connect
Inactive
5 rounds
IPOLatest

Undisclosed

Jul 2021

Series D

$175M

Jan 2021

Series C

$110M

Jan 2019

Series B

$45M

Jan 2017

Series A

$30M

Jan 2016

Frequently Asked Questions

What is Tempus's valuation?
At $8.1B, the company ranks among the AI unicorns tracked on Awaira.
Who invested in Tempus?
Investor details haven't been made public yet. Check back for updates as new funding rounds are announced.
When did Tempus last raise funding?
A IPO represents the most recent capital raise in July 2021.
How many employees does Tempus have?
The team is roughly 2500 people, headquartered in United States.
What does Tempus do?
Tempus is an AI-driven oncology and precision medicine company founded in 2015 that utilizes machine learning and data analysis to improve cancer treatment outcomes. The platform aggregates and analyzes vast datasets including clinical data, imaging, molecular information, and outcomes to identify personalized treatment strategies for cancer patients.
Who founded Tempus?
Eric Lefkofsky established the company in 2015. It's based in United States. Eric Lefkofsky serves as Founder & CEO.
Is Tempus profitable?
Profitability data isn't available in public filings. The company has raised $1.05B in total funding and operates at the Public stage.
Where is Tempus headquartered?
The headquarters sit in United States 🇺🇸 and was established in 2015. It competes in the AI Healthcare sector.
⚔️

Compare Tempus

See how Tempus stacks up against competitors in valuation, funding, team size, and Awaira Score.

Browse all comparisons →